Professor of Emerging Viruses
Carroll Group: High Consequence Emerging Viruses Group
HOST-PATHOGEN INTERACTIONS OF HIGH CONSEQUENCE EMERGING VIRUSES
Our work centres around high consequence emerging viral infections. Currently, our focus is on Ebola, Lassa fever and SARS-CoV-2. We are interested in host-pathogen interactions, development of anti-virals and recently we have been looking at the IgG response following SARS-CoV-2 infection and/or vaccination in humans and animal models. To further support this work we are using a live virus neutralisation, multiplex immunoassays and novel ACE2 inhibition assay to inform on the ability of serum to neutralise SARS-CoV-2 variants of concern (VOC). We are also interested in the innate response to viral infection, particularly activation and/or evasion of the complement system
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2.
Wilkinson T. et al, (2023), ERJ open research, 9, 249 - 2023
CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study.
Neale I. et al, (2023), mBio
Cellular immunity to SARS-CoV-2 following intrafamilial exposure in seronegative family members
Jay C. et al, (2023), Frontiers in Immunology, 14
Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history.
Hornsby H. et al, (2023), Nature communications, 14
Corrigendum: Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.
Thursz M. et al, (2023), The Journal of general virology, 104